TX-COGNITE
9.1.2023 15:36:39 CET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced four appointments to lead the company’s scaling efforts for its next stage of growth. Cognite's new executive leaders are Moe Tanabian, Chief Product Officer (CPO); Paul Lightfoot, SVP of User Experience; Emmanuelle Camus, President of Cognite EMEA; and Liat Berger, Chief Human Resources Officer (CHRO). These leaders held roles of increasing responsibility at Red Hat, Microsoft, Amazon, PTC, and Aker Solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230109005470/en/
L-R Liat Berger, CHRO; Moe Tanabian, CPO; Emmanuelle Camus, President EMEA; Paul Lightfoot, SVP UX (Photo: Business Wire)
Cognite’s CEO Girish Rishi said, "Building a high-performance team and developing our talent is a top priority. I'm pleased to welcome these leaders with diverse, global experiences, including deep technical skill sets and tenures at Fortune 500 companies. These accomplished executives will help us further scale our commitments to customers and partners as we solve the industrial data availability-to-value problem together."
Moe Tanabian, Cognite’s new Chief Product Officer, is charged with product strategy and execution, as well as product management, design, and engineering. He has been driving innovation at scale for nearly three decades, particularly in the areas of software products, AI, ML, and IoT. Tanabian recently served as Vice President and General Manager of Azure Light Edge for Microsoft, driving more than $2 billion P&L for Microsoft's portfolio of products in IoT, OT, and embedded industrial domains. Prior to his role at Microsoft, Tanabian worked for Samsung as Vice President of Smart Products and IoT, as well as Amazon, where he led the efforts to build and deliver the Amazon Android Appstore on Kindle Fire and Amazon Phone devices. Tanabian holds a master’s degree in Systems and Computer Engineering from Carleton University, Ottawa, Ontario and an MBA from the School of Business Queen’s University, Kingston, Ontario.
Liat Berger will serve as the new CHRO. She has a demonstrated track record of HR leadership with global multi-site companies and will help drive Cognite’s scale-up strategy. She has spent the last ten years at Aker Solutions and most recently served as Senior Vice President of People and Organization, Corporate, where she focused on business strategy by helping leaders identify, prioritize and build organizational capabilities, behaviors, and structures needed to support the change agenda. She also served as the Head of P&O for the Subsea Organization at Aker Solutions, which was composed of 4,500 employees distributed in 10 different locations on four different continents. Her expertise is building and balancing global companies while incorporating local realities, and she will play a key role in energizing Cognite’s global workforce. She is a graduate in Business Administration of Universidade Federal do Parana and has a specialization in Group Dynamics and People Management.
Emmanuelle Camus will assume the role of President of Cognite EMEA. She will focus on accelerating Cognite’s growth and strengthening the company’s position as a leading industrial software provider in the EMEA region in the Energy, Power, and Clean Tech and Manufacturing markets. Prior to joining Cognite, Camus spent 25 years at PTC in various leadership roles focused on business transformation and served most recently as their Senior Vice President of Alliances EMEAI. She has extensive experience in driving exponential growth in Europe & India through B2B sales and leveraging strategic alliances & partners and a strong background in solving Industry 4.0 challenges, digital transformation, Corporate Social Responsibility and Diversity, Equality & Inclusion. She is a graduate of NEOMA Business School.
Paul Lightfoot will support Tanabian as the new Senior Vice President of User Experience as Cognite doubles down on product design to allow customers to exponentially grow the number of data-literate industrial subject matter experts within their organizations. In his role, Lightfoot will lead Cognite's product design vision and strategy to meet these evolving needs as the OT industry is now being software-defined and is evolving into the fusing of physical and digital worlds at scale. Previously, he held product design leadership roles at several high-growth technology companies, most recently building out the product design/user experience practice at Red Hat as its Global Director, User Experience Product Design Team. Paul brings his passion for nurturing and developing a customer-obsessed culture to the role, as well as product management leadership and a focus on the discovery and development of product-market-fit. Paul has a degree in Management Information Systems from Bridgewater State University.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-heavy industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
